{"messages":[{"status":"ok","cursor":"2760","count":30,"total":9467}], "collection":[{"rel_doi":"10.1101\/2020.07.21.214056","rel_title":"Implications of the COVID-19 lockdown on dengue transmission and the occurrence of Aedes aegypti (Linnaeus) and Aedes albopictus (Skuse) in Malaysia","rel_date":"2020-07-21","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.21.214056","rel_abs":"The impact of movement restrictions during the COVID-19 lockdown on the existing endemic infectious disease dengue fever has generated considerable research interest. We compared the Malaysia weekly epidemiological records of dengue incidences during the period of lockdown to the trend of previous years (2015 to 2019) and a simulation at the corresponding period that expected no movement restrictions. We found that the dengue incidence declined significantly with a greater magnitude at phase 1 of lockdown, with a negative gradient of 3.2-fold steeper than the trend observed in previous years and 6.5-fold steeper than the simulation, indicating that the control of population movement did reduce dengue transmission. However, starting from phase 2 of lockdown, the dengue incidences demonstrated an elevation and earlier rebound by at least 4 weeks and grew with an exponential pattern compared to the simulation and previous years. Together with our data on Aedes mosquitoes from a district of Penang, Malaysia, we revealed that Aedes albopictus is the predominant species for both indoor and outdoor environments. The abundance of the mosquito was increasing steadily during the period of lockdown, and demonstrated strong correlation with the locally reported dengue incidences; therefore, we proposed the possible diffusive effect of vector that led to a higher acceleration of incidence rate. These findings would help authorities review the direction and efforts of the vector control strategy.","rel_num_authors":3,"rel_authors":[{"author_name":"Song-Quan Ong","author_inst":"UOW Malaysia KDU Penang University College"},{"author_name":"Hamdan Ahmad","author_inst":"Universiti Sains Malaysia"},{"author_name":"Ahmad Mohiddin Mohd. Ngesom","author_inst":"Universiti Kebangsaan Malaysia"}],"version":"1","license":"cc_by","type":"new results","category":"zoology"},{"rel_doi":"10.1101\/2020.07.19.20157511","rel_title":"Bioaersols in orthopedic surgical procedures and implications for clinical practice in the times of COVID-19 pandemic: a protocol for systematic review and meta-analysis","rel_date":"2020-07-21","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.19.20157511","rel_abs":"Background Orthopedic surgical procedures involve a number of aerosol generating procedures; these include electrocautery, power instruments for bone cutting, burring and drilling, and tools for wound lavage. This assumes a great significance in the context of the current COVD-19 pandemic, as there are chances of aerosol-borne disease transmission in orthopedic surgical procedures. Hence, this systematic review and meta-analysis will be undertaken to assimilate and analyse the available evidence on bioaerosols in orthopedic surgical procedures and their significance with respect to SARS-CoV-2 virus transmission. Objectives To determine the characteristics (amount and\/or density, size, infectivity, and spread etc.) of bioaerosols found in orthopaedic operating rooms (ORs) and to determine the characteristics of aerosols generated by different orthopaedic power tools and devices. Methods A systematic review and meta-analysis will be conducted. The PRISMA guidelines will be strictly followed. The primary search will be conducted on the PubMed, EMBASE, Scopus, Cochrane Library, medRxiv, bioRxix and Lancet preprint databases, using a well-defined search strategy. Any original research study (including cohort, case-control, case series, cadaveric studies and studies, animal models, laboratory based experimental studies) looking at aerosol generation in orthopedic surgical procedures, or aerosol generation by orthopaedic power tools and devices will included. Outcome measures will include characteristics (amount and\/or density, size, infectivity, and spread etc.) of bioaerosols found in orthopaedic operating rooms (ORs) and those generated by various orthopaedics power tools and devices. Metanalysis using the random-effects model will be conducted to determined pooled estimates of the outcome variables. Heterogeneity will be assessed by the I2 test. Risk of bias will be assessed by the Risk of Bias in Studies estimating Prevalence of Exposure to Occupational risk factors (RoB-SPEO) tool. The overall strength of evidence will be assessed by the GRADE approach.","rel_num_authors":5,"rel_authors":[{"author_name":"Siddhartha Sharma","author_inst":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"},{"author_name":"Rakesh John","author_inst":"Department of Trauma & Orthopedics, Hull University Teaching Hospitals, Hull, East Yorkshire, UK"},{"author_name":"Deepak Neradi","author_inst":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"},{"author_name":"Sandeep Patel","author_inst":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"},{"author_name":"Mandeep Singh Dhillon","author_inst":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"orthopedics"},{"rel_doi":"10.1101\/2020.07.19.20157354","rel_title":"The Effect of GDP and Distance on Timing of COVID-19 Spread in Chinese Provinces in 2020","rel_date":"2020-07-21","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.19.20157354","rel_abs":"The geographical spread of COVID-19 across China's provinces provides the opportunity for retrospective analysis on contributors to the timing of the spread. Highly contagious diseases need to be seeded into populations and we hypothesized that greater distance from the epicenter in Wuhan, as well as higher province-level GDP per capita, would delay the time until a province detected COVID-19 cases. To test this hypothesis, we used province-level socioeconomic data such as GDP per capita and percentage of the population aged over 65, distance from the Wuhan epicenter, and health systems capacity in a Cox proportional hazards analysis of the determinants of each province's time until epidemic start. The start was defined by the number of days it took for each province to reach thresholds of 3, 5, 10, or 100 cases. We controlled for the number of hospital beds and physicians as these could influence the speed of case detection. Surprisingly, none of the explanatory variables had a statistically significant effect on the time it took for each province to get its first cases; the timing of COVID-19 spread appears to have been random with respect to distance, GDP, demography, and the strength of the health system. Looking to other factors, such as travel, policy, and lockdown measures, could provide additional insights on realizing most critical factors in the timing of spread.","rel_num_authors":3,"rel_authors":[{"author_name":"Alice Kuan","author_inst":"Johns Hopkins University"},{"author_name":"Mingxin Chen","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"David Bishai","author_inst":"Johns Hopkins Bloomberg School of Public Health"},{"author_name":"Sandeep Patel","author_inst":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"},{"author_name":"Mandeep Singh Dhillon","author_inst":"Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"health economics"},{"rel_doi":"10.1101\/2020.07.19.211110","rel_title":"The short and long-range RNA-RNA Interactome of SARS-CoV-2","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.19.211110","rel_abs":"The Coronaviridae is a family of positive-strand RNA viruses that includes SARS-CoV-2, the etiologic agent of the COVID-19 pandemic. Bearing the largest single-stranded RNA genomes in nature, coronaviruses are critically dependent on long-distance RNA-RNA interactions to regulate the viral transcription and replication pathways. Here we experimentally mapped the in vivo RNA-RNA interactome of the full-length SARS-CoV-2 genome and subgenomic mRNAs. We uncovered a network of RNA-RNA interactions spanning tens of thousands of nucleotides. These interactions reveal that the viral genome and subgenomes adopt alternative topologies inside cells, and engage in different interactions with host RNAs. Notably, we discovered a long-range RNA-RNA interaction - the FSE-arch - that encircles the programmed ribosomal frameshifting element. The FSE-arch is conserved in the related MERS-CoV and is under purifying selection. Our findings illuminate RNA structure based mechanisms governing replication, discontinuous transcription, and translation of coronaviruses, and will aid future efforts to develop antiviral strategies.","rel_num_authors":6,"rel_authors":[{"author_name":"Omer Ziv","author_inst":"Wellcome Trust\/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, CB2 1QN, UK"},{"author_name":"Jonathan Price","author_inst":"Wellcome Trust\/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, CB2 1QN, UK"},{"author_name":"Lyudmila Shalamova","author_inst":"Institute for Virology, FB10-Veterinary Medicine, Justus-Liebig University, Giessen 35392, Germany"},{"author_name":"Tsveta Kamenova","author_inst":"Wellcome Trust\/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, CB2 1QN, UK"},{"author_name":"Friedemann Weber","author_inst":"Institute for Virology, FB10-Veterinary Medicine, Justus-Liebig University, Giessen 35392, Germany"},{"author_name":"Eric A. Miska","author_inst":"Wellcome Trust\/Cancer Research UK Gurdon Institute and Department of Genetics, University of Cambridge, Cambridge, CB2 1QN, UK"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"molecular biology"},{"rel_doi":"10.1101\/2020.07.19.210955","rel_title":"Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.19.210955","rel_abs":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes COVID-19, utilizes angiotensin-converting enzyme 2 (ACE2) for entry into target cells. ACE2 has been proposed as an interferon-stimulated gene (ISG). Thus, interferon-induced variability in ACE2 expression levels could be important for susceptibility to COVID-19 or its outcomes. Here, we report the discovery of a novel, primate-specific isoform of ACE2, which we designate as deltaACE2 (dACE2). We demonstrate that dACE2, but not ACE2, is an ISG. In vitro, dACE2, which lacks 356 N-terminal amino acids, was non-functional in binding the SARS-CoV-2 spike protein and as a carboxypeptidase. Our results reconcile current knowledge on ACE2 expression and suggest that the ISG-type induction of dACE2 in IFN-high conditions created by treatments, inflammatory tumor microenvironment, or viral co-infections is unlikely to affect the cellular entry of SARS-CoV-2 and promote infection.","rel_num_authors":14,"rel_authors":[{"author_name":"Olusegun O Onabajo","author_inst":"Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"author_name":"A Rouf Banday","author_inst":"Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"author_name":"Wusheng Yan","author_inst":"Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"author_name":"Adeola Obajemu","author_inst":"Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"author_name":"Megan L Stanifer","author_inst":"Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany"},{"author_name":"Deanna M Santer","author_inst":"Li Ka Shing Institute of Virology and Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada."},{"author_name":"Oscar Florez-Vargas","author_inst":"Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"author_name":"Helen Piontkivska","author_inst":"Department of Biological Sciences and Brain Health Research Institute, Kent State University, Kent, OH, USA"},{"author_name":"Joselin Vargas","author_inst":"Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA"},{"author_name":"Carmon Kee","author_inst":"Division of Cellular Polarity and Viral Infection, German Cancer Research Center (DKFZ); Department of Infectious Diseases, Virology, University Hospital Heidel"},{"author_name":"D Lorne Tyrrell","author_inst":"Li Ka Shing Institute of Virology and Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada."},{"author_name":"Juan L Mendoza","author_inst":"Pritzker School of Molecular Engineering and Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA"},{"author_name":"Steeve Boulant","author_inst":"Division of Cellular Polarity and Viral Infection, German Cancer Research Center (DKFZ); Department of Infectious Diseases, Virology, University Hospital Heidel"},{"author_name":"Ludmila Prokunina-Olsson","author_inst":"National Cancer Institute"}],"version":"1","license":"cc0","type":"new results","category":"genetics"},{"rel_doi":"10.1101\/2020.07.20.211789","rel_title":"A human disease model of SARS-CoV-2-induced lung injury and immune responses with a microengineered organ chip","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.20.211789","rel_abs":"Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that seriously endangers human health. There is an urgent need to build physiological relevant human models for deep understanding the complex organ-level disease processes and facilitating effective therapeutics for COVID-19. Here, we first report the use of microengineered alveolus chip to create a human disease model of lung injury and immune responses induced by native SARS-CoV-2 at organ-level. This biomimetic system is able to reconstitute the key features of human alveolar-capillary barrier by co-culture of alveolar epithelial and microvascular endothelial cells under microfluidic flow. The epithelial cells on chip showed higher susceptibility to SARS-CoV-2 infection than endothelial cells identified by viral spike protein expression. Transcriptional analysis showed distinct responses of two cell types to SARS-CoV-2 infection, including activated type I interferon (IFN-I) signaling pathway in epithelium and activated JAK-STAT signaling pathway in endothelium. Notably, in the presence of circulating immune cells, a series of alveolar pathological changes were observed, including the detachment of endothelial cells, recruitment of immune cells, and increased production of inflammatory cytokines (IL-6, IL-8, IL-1{beta} and TNF-). These new findings revealed a crucial role of immune cells in mediating lung injury and exacerbated inflammation. Treatment with antiviral compound remdesivir could suppress viral copy and alleviate the disruption of alveolar barrier integrity induced by viral infection. This bioengineered human organ chip system can closely mirror human-relevant lung pathogenesis and immune responses to SARS-CoV-2 infection, not possible by other in vitro models, which provides a promising and alternative platform for COVID-19 research and preclinical trials.","rel_num_authors":16,"rel_authors":[{"author_name":"Min Zhang","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China."},{"author_name":"Peng Wang","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China."},{"author_name":"Ronghua Luo","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Yaqing Wang","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Zhongyu Li","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China."},{"author_name":"Yaqiong Guo","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Yulin Yao","author_inst":"Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy o"},{"author_name":"Minghua Li","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Tingting Tao","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Wenwen Chen","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Jianbao Han","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Haitao Liu","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Kangli Cui","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Xu Zhang","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China."},{"author_name":"Yongtang Zheng","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Jianhua Qin","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; Institute for Stem Cell"}],"version":"1","license":"cc_no","type":"new results","category":"bioengineering"},{"rel_doi":"10.1101\/2020.07.11.20148486","rel_title":"COVID-19, Race, and Redlining","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.11.20148486","rel_abs":"Discussion on the disproportionate impact of COVID-19 on African Americans has been at center stage since the outbreak of the epidemic in the United States. To present day, however, lack of race-disaggregated individual data has prevented a rigorous assessment of the extent of this phenomenon and the reasons why blacks may be particularly vulnerable to the disease. Using individual and georeferenced death data collected daily by the Cook County Medical Examiner, we provide first evidence that race does affect COVID-19 outcomes. The data confirm that in Cook County blacks are overrepresented in terms of COVID-19 related deaths since - as of June 16, 2020 - they constitute 35 percent of the dead, so that they are dying at a rate 1.3 times higher than their population share. Furthermore, by combining the spatial distribution of mortality with the 1930s redlining maps for the Chicago area, we obtain a block group level panel dataset of weekly deaths over the period January 1, 2020-June 16, 2020, over which we establish that, after the outbreak of the epidemic, historically lower-graded neighborhoods display a sharper increase in mortality, driven by blacks, while no pre-treatment differences are detected. Thus, we uncover a persistence influence of the racial segregation induced by the discriminatory lending practices of the 1930s, by way of a diminished resilience of the black population to the shock represented by the COVID-19 outbreak. A heterogeneity analysis reveals that the main channels of transmission are socioeconomic status and household composition, whose influence is magnified in combination with a higher black share.","rel_num_authors":2,"rel_authors":[{"author_name":"Graziella Bertocchi","author_inst":"University of Modena and Reggio Emilia and EIEF"},{"author_name":"Arcangelo Dimico","author_inst":"Queen's University Belfast"},{"author_name":"Ronghua Luo","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Yaqing Wang","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Zhongyu Li","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China."},{"author_name":"Yaqiong Guo","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Yulin Yao","author_inst":"Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy o"},{"author_name":"Minghua Li","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Tingting Tao","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Wenwen Chen","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Jianbao Han","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Haitao Liu","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Kangli Cui","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; University of Chinese A"},{"author_name":"Xu Zhang","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China."},{"author_name":"Yongtang Zheng","author_inst":"Kunming National High-level Bio-safety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy "},{"author_name":"Jianhua Qin","author_inst":"Division of Biotechnology, CAS Key Laboratory of SSAC, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China; Institute for Stem Cell"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"health economics"},{"rel_doi":"10.1101\/2020.07.15.20150490","rel_title":"Observational Study of Haloperidol in Hospitalized Patients with Covid-19","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.15.20150490","rel_abs":"Background: Haloperidol, a widely used antipsychotic, has been suggested as potential effective treatment for Covid-19 on the grounds of its in-vitro antiviral effects against SARS-CoV-2. Methods: We examined the association between haloperidol use and respiratory failure at AP-HP Greater Paris University hospitals. Data were obtained regarding all adult patients hospitalized with Covid-19 since the beginning of the epidemic. Study baseline was defined as the date of hospital admission. The primary endpoint was a composite of intubation or death and the secondary endpoint was discharge home among survivors in time-to-event analyses. We compared outcomes between patients who were exposed to haloperidol and those who were not, using a multivariable Cox regression model with inverse probability weighting according to the propensity score. Results: Of the 13,279 hospitalized adult patients with positive Covid-19 RT-PCR test, 667 patients (5.0%) were excluded because of missing data. Of the remaining 12,612 patients, 104 (0.8%) were exposed to haloperidol. Over a mean follow-up of 20.8 days, the primary endpoint of respiratory failure respectively occurred in 27 patients (26.0%) exposed to haloperidol and 1,700 patients (13.6%) who were not. Among survivors, the secondary endpoint of discharge home occurred in 26 patients (32.1%) who received haloperidol and 6,110 patients (55.3%) who did not. In the main analysis, there were no significant associations between haloperidol use and the primary (HR, 1.09; 95% CI, 0.60 to 1.97, p=0.772) and secondary (HR, 0.88; 95% CI, 0.50 to 1.53, p=0.643) endpoints. Results were similar in multiple sensitivity analyses. Conclusion: In this observational study involving patients with Covid-19 who had been admitted to the hospital, haloperidol use was not associated with risk of intubation or death, or with time to hospital discharge home. These results suggest that haloperidol is unlikely to have a clinical efficacy for Covid-19.","rel_num_authors":16,"rel_authors":[{"author_name":"Nicolas HOERTEL","author_inst":"Universite de Paris"},{"author_name":"Marina SANCHEZ RICO","author_inst":"Universidad Complutense de Madrid"},{"author_name":"Raphael VERNET","author_inst":"AP-HP"},{"author_name":"Anne-Sophie JANNOT","author_inst":"AP-HP"},{"author_name":"Antoine NEURAZ","author_inst":"AP-HP"},{"author_name":"Carlos BLANCO","author_inst":"National Institute on Drug Abuse"},{"author_name":"Cedric LEMOGNE","author_inst":"Universite de Paris"},{"author_name":"Guillaume AIRAGNES","author_inst":"Universite de Paris"},{"author_name":"Nicolas PARIS","author_inst":"AP-HP"},{"author_name":"Christel DANIEL","author_inst":"AP-HP"},{"author_name":"Alexandre GRAMFORT","author_inst":"INRIA"},{"author_name":"Guillaume LEMAITRE","author_inst":"INRIA"},{"author_name":"Melodie BERNAUX","author_inst":"AP-HP"},{"author_name":"Ali BELLAMINE","author_inst":"AP-HP"},{"author_name":"Nathanael BEEKER","author_inst":"AP-HP"},{"author_name":"Frederic LIMOSIN","author_inst":"Universite de Paris"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.18.20155374","rel_title":"Dynamics and significance of the antibody response to SARS-CoV-2 infection","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.18.20155374","rel_abs":"BACKGROUND Characterizing the humoral immune response to SARS-CoV-2 and developing accurate serologic assays are needed for diagnostic purposes and estimating population-level seroprevalence. METHODS We measured the kinetics of early antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in a cohort of 259 symptomatic North American patients infected with SARS-CoV-2 (up to 75 days after symptom onset) compared to antibody levels in 1548 individuals whose blood samples were obtained prior to the pandemic. RESULTS Between 14-28 days from onset of symptoms, IgG, IgA, or IgM antibody responses to RBD were all accurate in identifying recently infected individuals, with 100% specificity and a sensitivity of 97%, 91%, and 81% respectively. Although the estimated median time to becoming seropositive was similar across isotypes, IgA and IgM antibodies against RBD were short-lived with most individuals estimated to become seronegative again by 51 and 47 days after symptom onset, respectively. IgG antibodies against RBD lasted longer and persisted through 75 days post-symptoms. IgG antibodies to SARS-CoV-2 RBD were highly correlated with neutralizing antibodies targeting the S protein. No cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies was observed with several known circulating coronaviruses, HKU1, OC 229 E, OC43, and NL63. CONCLUSIONS Among symptomatic SARS-CoV-2 cases, RBD-targeted antibodies can be indicative of previous and recent infection. IgG antibodies are correlated with neutralizing antibodies and are possibly a correlate of protective immunity.","rel_num_authors":35,"rel_authors":[{"author_name":"Anita S Iyer","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Forrest K Jones","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Ariana Nodoushania","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Meagan Kelly","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Margaret Becker","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Damien Slater","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Rachel Mills","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Erica Teng","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Mohammad Kamruzzaman","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Wilfredo F Garcia-Beltran","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.17.20152702","rel_title":"Evaluation of efficiency and sensitivity of 1D and 2D sample pooling strategies for diagnostic screening purposes","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.17.20152702","rel_abs":"As SARS-CoV-2 continues to spread around the world while the pandemic lasts, testing facilities are forced to massively increment their testing capacities to handle the increasing number of samples. While sample pooling methods have been proposed or are effectively implemented in some labs, no systematic and large-scale simulations have been performed using real-life quantitative data from testing facilities. Here, we use anonymous data from 1632 positive cases to simulate and compare 1D and 2D pooling strategies. We show that the choice of pooling method and pool size is an intricate decision with a prevalence-dependent efficiency-sensitivity trade-off.","rel_num_authors":3,"rel_authors":[{"author_name":"Jasper Verwilt","author_inst":"Ghent University"},{"author_name":"Pieter Mestdagh","author_inst":"Ghent University"},{"author_name":"Jo Vandesompele","author_inst":"Ghent University"},{"author_name":"Meagan Kelly","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Margaret Becker","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Damien Slater","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Rachel Mills","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Erica Teng","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Mohammad Kamruzzaman","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Wilfredo F Garcia-Beltran","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.07.09.20149450","rel_title":"Genetic validation of the use of tocilizumab, statins and dexamethasone in COVID-19","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.09.20149450","rel_abs":"Background: New means of treating COVID-19 are urgently needed. Genetic validation of drugs can foreshadow trial results, and help prioritize investigations. We assessed whether common drugs, suggested as possible treatments for COVID-19 (tocilizumab, anakinra and statins) with established genetic proxies, are effective in COVID-19. We also included dexamethasone as a positive control exposure because the RECOVERY trial suggested benefit in severe COVID-19. Methods: We assessed, using Mendelian randomization, whether genetic proxies of tocilizumab, anakinra, statins and dexamethasone use affected risk of very severe (cases=536, non-cases=329391) or hospitalized (cases=3199, non-cases=897488) COVID-19 using a recent genome-wide association study. Results: Using rs2228145 (IL6R) to proxy effects of tocilizumab use, no association with very severe COVID-19 was found, but possibly an inverse association with hospitalized COVID-19 (odds ratio (OR) 0.83 per standardized effect of higher soluble interleukin-6r, 95% confidence interval 0.67 to 1.02). Using rs12916 (HMGCR) to proxy effects of statins use, an inverse association with very severe COVID-19 was found (OR 0.30 per standardized effect, 95% CI 0.10 to 0.89). Using rs6743376 and rs1542176 to proxy effects of anakinra use, no associations with COVID-19 were found. Dexamethasone, instrumented by cortisol, was possibly inversely associated with very severe COVID-19 (OR 0.20 per standardized effect 95% CI 0.04 to 1.04). Conclusion: Our study provides some genetic validation for the use of both tocilizumab and statins in COVID-19, but not anakinra, whilst being consistent with the findings from the RECOVERY trial about dexamethasone. Investigation of the underlying mechanisms might facilitate re-purposing and development of effective treatments.","rel_num_authors":4,"rel_authors":[{"author_name":"C M Schooling","author_inst":"The University of Hong Kong and CUNY SPH"},{"author_name":"SL Au Yeung","author_inst":"The University of Hong Kong"},{"author_name":"MK Kwok","author_inst":"The University of Hong Kong"},{"author_name":"JV Zhao","author_inst":"The University of Hong Kong"},{"author_name":"Margaret Becker","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Damien Slater","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Rachel Mills","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Erica Teng","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Mohammad Kamruzzaman","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Wilfredo F Garcia-Beltran","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.07.15.20154336","rel_title":"Epidemiological Profile and Transmission Dynamics of COVID-19 in the Philippines","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.15.20154336","rel_abs":"The Philippines confirmed local transmission of COVID-19 on 7 March 2020. We described the characteristics and epidemiological time-to-event distributions for laboratory-confirmed cases in the Philippines. The median age of 8,212 cases was 46 years (IQR: 32-61), with 46.2% being female and 68.8% living in the National Capital Region. Health care workers represented 24.7% of all detected infections. Mean length of hospitalization for those who were discharged or died were 16.00 days (95% CI: 15.48, 16.54) and 7.27 days (95% CI: 6.59, 8.24). Mean duration of illness was 26.66 days (95% CI: 26.06, 27.28) and 12.61 days (95% CI: 11.88, 13.37) for those who recovered or died. Mean serial interval was 6.90 days (95% CI: 5.81, 8.41). Epidemic doubling time pre-quarantine (11 February and 19 March) was 4.86 days (95% CI: 4.67, 5.07) and the reproductive number was 2.41 (95% CI: 2.33, 2.48). During quarantine (March 20 to April 9), doubling time was 12.97 days (95% CI: 12.57, 13.39) and the reproductive number was 0.89 (95% CI: 0.78, 1.02).","rel_num_authors":3,"rel_authors":[{"author_name":"Nel Jason Ladiao Haw","author_inst":"Ateneo de Manila University"},{"author_name":"Jhanna Uy","author_inst":"Ateneo de Manila University"},{"author_name":"Karla Therese L. Sy","author_inst":"Boston University"},{"author_name":"JV Zhao","author_inst":"The University of Hong Kong"},{"author_name":"Margaret Becker","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Damien Slater","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Rachel Mills","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Erica Teng","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Mohammad Kamruzzaman","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Wilfredo F Garcia-Beltran","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.07.18.20152256","rel_title":"Providing breastfeeding support during the COVID-19 pandemic: Concerns of mothers who contacted the Australian Breastfeeding Association","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.18.20152256","rel_abs":"Concerns of mothers seeking breastfeeding support during the COVID-19 pandemic, and the experiences of Australian Breastfeeding Association (ABA) volunteers who assisted them, were explored via an online survey. Surveys were completed 16th March to 18th of May 2020 and described the COVID-19 related concerns of 340 individuals. One hundred and thirty six mothers (64%) sought support to protect their infants by continuing breastfeeding, increasing milk supply, or restarting breastfeeding. Mothers were commonly stressed, isolated and needing reassurance. Thirty four (10%) raised concerns about COVID-19 and breastfeeding safety. One hundred and twenty nine (61%) informed volunteers they were unable to access face-to-face health services because of fear or unavailability. Most common breastfeeding concerns were related to insufficient milk or weight gain, painful breasts, relactation, and reducing supplemental milk. Volunteers reported mothers were worried stress had reduced milk supply, that milk supply concerns were exacerbated by the inability to weigh infants, and that seeking medical treatment was being delayed. ABA volunteers stated they felt supported and confident assisting mothers while also expressing distress at mothers situation. ABAs role in emergency response should be recognised and national planning for infant and young child feeding in emergencies, must be urgently developed, funded, and implemented.","rel_num_authors":3,"rel_authors":[{"author_name":"Naomi Hull","author_inst":"Australian Breastfeeding Association"},{"author_name":"Renee L Kam","author_inst":"Australian Breastfeeding Association"},{"author_name":"Karleen D Gribble","author_inst":"Western Sydney University"},{"author_name":"JV Zhao","author_inst":"The University of Hong Kong"},{"author_name":"Margaret Becker","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Damien Slater","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Rachel Mills","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Erica Teng","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Mohammad Kamruzzaman","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Wilfredo F Garcia-Beltran","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"pediatrics"},{"rel_doi":"10.1101\/2020.07.16.20152033","rel_title":"An Optimization Framework to Study the Balance Between Expected Fatalities due to COVID-19 and the Reopening of U.S. Communities","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.16.20152033","rel_abs":"As communities reopen following shelter-in-place orders, they are facing two conflicting objectives. The first is to keep the COVID-19 fatality rate down. The second is to revive the U.S. economy and the livelihood of millions of Americans. In this paper, a team of researchers from the Center on Stochastic Modeling, Optimization, & Statistics (COSMOS) at the University of Texas at Arlington, in collaboration with researchers from University of Texas Southwestern Medical Center and Harvard Medical School, has formulated a computationally-efficient optimization framework, referred to as COSMOS COVID-19 Linear Programming (CC19LP), to study the delicate balance between the expected fatality rate and the level of normalcy in the community. Given the disproportionate fatality characteristics of COVID-19 among those in different age groups or with an underlying medical condition or those living with crowding, the key to the CC19LP framework is a focus on \"key contacts\" that separate individuals at higher risk from the rest of the population. The philosophy of CC19LP lies in maximizing protection of key contacts, so as to shield high-risk individuals from infection. Given the lack of pharmaceutical solutions, i.e., a vaccine or cure, the CC19LP framework minimizes expected fatalities by optimizing the use of non-pharmaceutical interventions, namely COVID-19 testing; personal protective equipment; and social precautions, such as distancing, hand-washing, and face coverings. Low-risk individuals that are not key contacts, including most children, are unrestricted and can choose to participate in pre-pandemic normal activities, which eliminates the need for compliance across the entire population. Consequently, the CC19LP framework demonstrates optimal strategies for protecting high-risk individuals while reopening communities.","rel_num_authors":10,"rel_authors":[{"author_name":"Victoria C. P. Chen","author_inst":"University of Texas at Arlington"},{"author_name":"Yuan Zhou","author_inst":"University of Texas at Arlington"},{"author_name":"Alireza Fallahi","author_inst":"University of Texas at Arlington"},{"author_name":"Amith Viswanatha","author_inst":"University of Texas at Arlington"},{"author_name":"Yasaman Ghasemi","author_inst":"University of Texas at Arlington"},{"author_name":"Nilabh S. Ohol","author_inst":"University of Texas at Arlington"},{"author_name":"Jay M. Rosenberger","author_inst":"University of Texas at Arlington"},{"author_name":"Feng Liu","author_inst":"Harvard Medical School"},{"author_name":"Xinglong Ju","author_inst":"University of Texas Southwestern Medical Center"},{"author_name":"Jeffrey B. Guild","author_inst":"University of Texas Southwestern Medical Center"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.07.14.20151415","rel_title":"The brief comparison of the operational efficiency of pool-testing strategies for COVID-19 mass testing in PCR laboratories","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.14.20151415","rel_abs":"This paper addresses the operational efficiency of different pool-testing strategies in typical scenarios of a PCR laboratory working in mass testing for COVID-19 with different values of prevalence, limitations and conditions of testing, and priorities of optimization. The research employs a model of the laboratory's testing process, created after interviewing of PCR laboratories and studying their operations. The limitations and operational characteristics of this model were applied in a simulation of the testing process with different pool-testing strategies managed by a computer program developed in the LOMT project. The efficiency indicators assessed are the number of assays needed to obtain results of a batch of specimens, the number of specimens identified after the first analysis, and total time to obtain all results. Depending on prevalence, constraints of testing, and priorities of optimization, different pool-testing strategies provide the best operational efficiency. The binary splitting algorithm provides the maximum reduction of the number of assays: from 1.99x reduction for a high prevalence (10%) to 25x reduction for a low prevalence (0.1%), while other algorithms provide the least amount of time to obtain results or the maximum number of the specimens classified after the first analysis.","rel_num_authors":1,"rel_authors":[{"author_name":"Kirill Vechera","author_inst":"Jetware"},{"author_name":"Yuan Zhou","author_inst":"University of Texas at Arlington"},{"author_name":"Alireza Fallahi","author_inst":"University of Texas at Arlington"},{"author_name":"Amith Viswanatha","author_inst":"University of Texas at Arlington"},{"author_name":"Yasaman Ghasemi","author_inst":"University of Texas at Arlington"},{"author_name":"Nilabh S. Ohol","author_inst":"University of Texas at Arlington"},{"author_name":"Jay M. Rosenberger","author_inst":"University of Texas at Arlington"},{"author_name":"Feng Liu","author_inst":"Harvard Medical School"},{"author_name":"Xinglong Ju","author_inst":"University of Texas Southwestern Medical Center"},{"author_name":"Jeffrey B. Guild","author_inst":"University of Texas Southwestern Medical Center"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"public and global health"},{"rel_doi":"10.1101\/2020.07.05.20146654","rel_title":"A student made MOOC for medical students during the SARS-CoV-2 pandemic.","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.05.20146654","rel_abs":"Background: Latin America was one of the last regions of the world to become affected by the COVID-19 pandemic. As a response to the emergency virtual education was implemented in almost every country of the region. Methods: a massive open online course about epilepsy was made using only free software and platforms following the international league against epilepsy competence-based domains for epileptology teaching. Results: 250 healthcare students signed up for the course and only 17.2% of them had previously participated in courses like this one. This course had a completion rate of 37.2% and of the students that completed the course 98.3% would participate in course like this in the future. Conclusion: In conclusion MOOCs can be easily implemented as a powerful pedagogic strategy during the COVID-19 pandemic and can have a positive impact not only in in its proposed learning objectives but it can help closing the gap that prevent Latin American healthcare students to acquire actively knowledge trough them.","rel_num_authors":1,"rel_authors":[{"author_name":"David Ramirez","author_inst":"Universidad pedagogica y Tecnologica de Colombia."},{"author_name":"Yuan Zhou","author_inst":"University of Texas at Arlington"},{"author_name":"Alireza Fallahi","author_inst":"University of Texas at Arlington"},{"author_name":"Amith Viswanatha","author_inst":"University of Texas at Arlington"},{"author_name":"Yasaman Ghasemi","author_inst":"University of Texas at Arlington"},{"author_name":"Nilabh S. Ohol","author_inst":"University of Texas at Arlington"},{"author_name":"Jay M. Rosenberger","author_inst":"University of Texas at Arlington"},{"author_name":"Feng Liu","author_inst":"Harvard Medical School"},{"author_name":"Xinglong Ju","author_inst":"University of Texas Southwestern Medical Center"},{"author_name":"Jeffrey B. Guild","author_inst":"University of Texas Southwestern Medical Center"},{"author_name":"Michael Astudillo","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Diane Yang","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Tyler E Miller","author_inst":"Massachusetts General Hospital"},{"author_name":"Elizabeth Oiver","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephanie Fischinger","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Caroline Atyeo","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Anthony John Iafrate","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen B Calderwood","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Stephen A Lauer","author_inst":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"author_name":"Jingyou Yu","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Zhenfeng Li","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard"},{"author_name":"Jared Feldman","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Blake M Hauser","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Timothy M Cardonna","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"John A Branda","author_inst":"Department of Pathology, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Sarah E Turbett","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Regina C LaRocque","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Guillaume Mellon","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Dan H Barouch","author_inst":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  School, Boston, MA, USA"},{"author_name":"Aaron G Schmidt","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Andrew S Azman","author_inst":"Johns Hopkins University"},{"author_name":"Galit Alter","author_inst":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA"},{"author_name":"Edward T Ryan","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Jason B Harris","author_inst":"Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA"},{"author_name":"Richelle C Charles","author_inst":"Massachusetts General Hospital"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"medical education"},{"rel_doi":"10.1101\/2020.07.17.20140533","rel_title":"Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.17.20140533","rel_abs":"An effective vaccine is needed to halt the spread of the SARS-CoV-2 pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1\/2 COVID-19 vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Here we present antibody and T cell responses after BNT162b1 vaccination from a second, non-randomized open-label phase 1\/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 g of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a COVID-19 convalescent human serum panel (HCS). Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 g) to 3.5-fold (50 g) those of HCS. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had TH1 skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon (IFN){gamma} was produced by a high fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.","rel_num_authors":42,"rel_authors":[{"author_name":"Ugur Sahin","author_inst":"BioNTech"},{"author_name":"Alexander Muik","author_inst":"BioNTech"},{"author_name":"Evelyna Derhovanessian","author_inst":"BioNTech"},{"author_name":"Isabel Vogler","author_inst":"BioNTech"},{"author_name":"Lena M Kranz","author_inst":"BioNTech"},{"author_name":"Mathias Vormehr","author_inst":"BioNTech"},{"author_name":"Alina Baum","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"Kristen Pascal","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"Jasmin Quandt","author_inst":"BioNTech"},{"author_name":"Daniel Maurus","author_inst":"BioNTech"},{"author_name":"Sebastian Brachtendorf","author_inst":"BioNTech"},{"author_name":"Verena L Loerks","author_inst":"BioNTech"},{"author_name":"Julian Sikorski","author_inst":"BioNTech"},{"author_name":"Rolf Hilker","author_inst":"BioNTech"},{"author_name":"Dirk Becker","author_inst":"BioNTech"},{"author_name":"Ann-Kathrin Eller","author_inst":"BioNTech"},{"author_name":"Jan Gruetzner","author_inst":"BioNTech"},{"author_name":"Carsten Boesler","author_inst":"BioNTech"},{"author_name":"Corinna Rosenbaum","author_inst":"BioNTech"},{"author_name":"Marie-Cristine Kuehnle","author_inst":"BioNTech"},{"author_name":"Ulrich Luxemburger","author_inst":"BioNTech"},{"author_name":"Alexandra Kemmer-Brueck","author_inst":"BioNTech"},{"author_name":"David Langer","author_inst":"BioNTech"},{"author_name":"Martin Bexon","author_inst":"Bexon Clinical Consulting LLC"},{"author_name":"Stefanie Bolte","author_inst":"BioNTech"},{"author_name":"Katalin Kariko","author_inst":"BioNTech"},{"author_name":"Tania Palanche","author_inst":"BioNTech"},{"author_name":"Boris Fischer","author_inst":"BioNTech"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.14.20144469","rel_title":"Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.14.20144469","rel_abs":"Introduction: Hospital mortality due to COVID-19 in Mexico is high (32%) and as of today, effective treatment options are limited. More effective treatments that shorten hospital stay and reduce mortality are needed. Initial reports for the use of convalescent plasma (CP) therapy for COVID-19 appear promising. We describe a case series of eight patients with impending respiratory failure, who underwent CP therapy. Methods: Six male and two female (ages 31 to 79) patients that were admitted to the intensive-care unit for severe COVID-19 were transfused with two doses of CP (250 mL per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected males who remained asymptomatic for > 7 days and were negative for two nasopharyngeal RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest X-ray findings and viral loads were analyzed before and after CP administration. Viral load association to disease severity was further analyzed on a separate cohort of asymptomatic vs hospitalized patients with COVID-19. Results: Eight patients with respiratory failure were successfully discharged with a median length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of C-reactive protein (CRP) (median, 22.80 mg\/dL vs. 1.63 mg\/dL), and of procalcitonin (median, 0.27 ng\/mL vs. 0.13 ng\/mL). High-Sensitivity Cardiac Troponin I (hs-cTnI), Brain Natriuretic Peptide (BNP) and Lactate Dehydrogenase (LDH) were lower, and a mild reduction of pulmonary infiltrates by chest X-ray was observed. Lastly, a reduction of viral load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]). We observed no adverse effects. Conclusions: CP could potentially be an effective therapeutic option for patients with severe COVID-19. Clinical benefit needs to be studied further through randomized controlled trials.","rel_num_authors":28,"rel_authors":[{"author_name":"Michel F. Martinez-Resendez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fernando Castilleja-Leal","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alejandro Torres-Quintanilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Augusto Rojas-Martinez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Gerardo Garcia-Rivas","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Rocio Ortiz-Lopez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Victor Trevino","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Reynaldo Lara-Medrano","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Hiram Villanueva-Lozano","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Teresa Ramirez-Elizondo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Victor Sanchez-Nava","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco Moreno-Hoyos","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alfonso Martinez-Thomae","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Martin Hernandez-Torre","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Carlos Diaz-Olachea","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Servando Cardona-Huerta","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Sylvia de la Rosa-Pacheco","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Carlos Diaz-Garza","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.13.20146175","rel_title":"Qing Fei Pai Du Tang, a Chinese multi-herbal medicine formulated against COVID-19, elevates the plasma levels of IL-1\u03b2, IL-18, TNF-\u03b1, and IL-8","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.13.20146175","rel_abs":"There are currently no specific vaccine or drugs proven to be effective against COVID-19. Traditional Chinese herbal medicine has been integrated into the official therapeutic protocol against COVID-19 in China. Qing Fei Pai Du Tang (QFPDT) is a Chinese multi-herbal formula newly developed and specifically optimized for the treatment of COVID-19. Therapeutic administration of QFPDT resulted in an improved cure rate in mild to critically-ill patients. However, the immunological mechanism for the efficacy of QFPDT has been poorly understood. Furthermore, the feasibility of prophylactic use in uninfected individuals remain unconfirmed. We thus examined whether the administration of QFPDT at a dose lower than recommended for therapeutic use alters hematological and\/or immunological measures in healthy individuals. We found that QFPDT elevates the plasma levels of IL-1{beta}, IL-18, TNF-, and IL-8, which are key mediators of acute inflammatory responses to ssRNA viruses. No apparent adverse effects were observed during the trial. Our finding suggests that the pharmacological action of QFPDT is associated with the upregulation of a subset of proinflammatory cytokines despite its clinical benefits for COVID-19 patients. We should therefore be careful in its prophylactic use in uninfected individuals until we have a better understanding of the immunopharmacological action of QFPDT through further clinical studies with larger cohorts.","rel_num_authors":7,"rel_authors":[{"author_name":"Yasunari Kageyama","author_inst":"Takanawa Clinic"},{"author_name":"Koichi Aida","author_inst":"Takanawa Clinic"},{"author_name":"Kimihiko Kawauchi","author_inst":"Takanawa Clinic"},{"author_name":"Masafumi Morimoto","author_inst":"Takanawa Clinic"},{"author_name":"Tomoka Ebisui","author_inst":"Takanawa Clinic"},{"author_name":"Tetsu Akiyama","author_inst":"Institute for Quantitative Biosciences, The University of Tokyo"},{"author_name":"Tsutomu Nakamura","author_inst":"Institute for Quantitative Biosciences, The University of Tokyo"},{"author_name":"Reynaldo Lara-Medrano","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Hiram Villanueva-Lozano","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Teresa Ramirez-Elizondo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Victor Sanchez-Nava","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco Moreno-Hoyos","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alfonso Martinez-Thomae","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Martin Hernandez-Torre","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Carlos Diaz-Olachea","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Servando Cardona-Huerta","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Sylvia de la Rosa-Pacheco","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Carlos Diaz-Garza","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.13.20041632","rel_title":"The Infectious Nature of Patient-Generated SARS-CoV-2 Aerosol","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.13.20041632","rel_abs":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission causing coronavirus disease 2019 (COVID-19) may occur through multiple routes. We collected aerosol samples around six patients admitted into mixed acuity wards in April of 2020 to identify the risk of airborne SARS-CoV-2. Measurements were made to characterize the size distribution of aerosol particles, and size-fractionated, aerosol samples were collected to assess the presence of infectious virus in particles sizes of >4.1 m, 1-4 m, and <1 m in the patient environment. Samples were analyzed by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), cell culture, western blot, and transmission electron microscopy (TEM). SARS-CoV-2 RNA was detected in all six rooms in all particle size fractions (>4.1 m, 1-4 m, and <1 m). Increases in viral RNA during cell culture of the virus from recovered aerosol samples demonstrated the presence of infectious, replicating virions in three <1 m aerosol samples (P<0.05). Viral replication of aerosol was also observed in the 1-4 m stage but did not reach statistical significance (0.05<P<0.10). Western blot and TEM analysis of these samples also showed evidence of viral proteins and intact virions. The infectious nature of aerosol collected in this study further suggests that airborne transmission of COVID-19 is possible, and that aerosol prevention measures are necessary to effectively stem the spread of SARS-CoV-2.","rel_num_authors":13,"rel_authors":[{"author_name":"Joshua L Santarpia","author_inst":"University of Nebraska Medical Center"},{"author_name":"Vicki L Herrera","author_inst":"University of Nebraska Medical Center"},{"author_name":"Danielle N Rivera","author_inst":"National Strategic Research Institute"},{"author_name":"Shanna Ratnesar-Shumate","author_inst":"University of Nebraska Medical Center"},{"author_name":"St. Patrick Reid","author_inst":"University of Nebraska Medical Cener"},{"author_name":"Paul W Denton","author_inst":"University of Nebraska Omaha"},{"author_name":"Jacob W.S. Martens","author_inst":"University of Nebraska Omaha"},{"author_name":"Ying Fang","author_inst":"Univsersity of Illinois at Urbana-Champaign"},{"author_name":"Nicholas Conoan","author_inst":"University of Nebraska Medical Center"},{"author_name":"Michael V Callahan","author_inst":"Harvard Univsersity"},{"author_name":"James V Lawler","author_inst":"University of Nebraska Medical Center"},{"author_name":"David M Brett-Major","author_inst":"University of Nebraska Medical Center"},{"author_name":"John J Lowe","author_inst":"University of Nebraska Medical Center"},{"author_name":"Martin Hernandez-Torre","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Carlos Diaz-Olachea","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Servando Cardona-Huerta","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Sylvia de la Rosa-Pacheco","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Carlos Diaz-Garza","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.19.20152322","rel_title":"Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.19.20152322","rel_abs":"From February to April, 2020, Lombardy (Italy) was the area who worldwide registered the highest numbers of SARS-CoV-2 infection. By extensively analyzing 346 whole SARS-CoV-2 genomes, we demonstrated the simultaneous circulation in Lombardy of two major viral lineages, likely derived from multiple introductions, occurring since the second half of January. Seven single nucleotide polymorphisms (five of them non-synonymous) characterized the SARS-CoV-2 sequences, none of them affecting N-glycosylation sites. These two lineages, and the presence of two well defined clusters inside Lineage 1, revealed that a sustained community transmission was ongoing way before the first COVID-19 case found in Lombardy.","rel_num_authors":18,"rel_authors":[{"author_name":"Claudia Alteri","author_inst":"University of Milan"},{"author_name":"Valeria Cento","author_inst":"University of Milan"},{"author_name":"Antonio Piralla","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Valentino Costabile","author_inst":"University of Milan"},{"author_name":"Monica Tallarita","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Luna Colagrossi","author_inst":"Bambino Gesu Children's Hospital"},{"author_name":"Silvia Renica","author_inst":"University of Milan"},{"author_name":"Federica Giardina","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Federica Novazzi","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Stefano Gaiarsa","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Elisa Matarazzo","author_inst":"University of Milan"},{"author_name":"Maria Antonello","author_inst":"University of Milan"},{"author_name":"Chiara Vismara","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Roberto Fumagalli","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Oscar Massimiliano Epis","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Massimo Puoti","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Carlo Federico Perno","author_inst":"University of Milan"},{"author_name":"Fausto Baldanti","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"infectious diseases"},{"rel_doi":"10.1101\/2020.07.18.210120","rel_title":"High expression of angiotensin-converting enzyme-2 (ACE2) on tissue macrophages that may be targeted by virus SARS-CoV-2 in COVID-19 patients","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.18.210120","rel_abs":"Angiotensin-converting enzyme-2 (ACE2) has been recognized as the binding receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that infects host cells, causing the development of the new coronavirus infectious disease (COVID-19). To better understand the pathogenesis of COVID-19 and build up the host anti-viral immunity, we examined the levels of ACE2 expression on different types of immune cells including tissue macrophages. Flow cytometry demonstrated that there was little to no expression of ACE2 on most of the human peripheral blood-derived immune cells including CD4+ T, CD8+ T, activated CD4+ T, activated CD8+ T, CD4+CD25+CD127low\/- regulatory T cells (Tregs), Th17 cells, NKT cells, B cells, NK cells, monocytes, dendritic cells (DCs), and granulocytes. Additionally, there was no ACE2 expression (< 1%) found on platelets. Compared with interleukin-4-treated type 2 macrophages (M2), the ACE2 expression was markedly increased on the activated type 1 macrophages (M1) after the stimulation with lipopolysaccharide (LPS). Immunohistochemistry demonstrated that high expressions of ACE2 were colocalized with tissue macrophages, such as alveolar macrophages found within the lungs and Kupffer cells within livers of mice. Flow cytometry confirmed the very low level of ACE2 expression on human primary pulmonary alveolar epithelial cells. These data indicate that alveolar macrophages, as the frontline immune cells, may be directly targeted by the SARS-CoV-2 infection and therefore need to be considered for the prevention and treatment of COVID-19.","rel_num_authors":6,"rel_authors":[{"author_name":"Xiang Song","author_inst":"Center for Discovery and Innovation, Hackensack Meridian Health"},{"author_name":"Wei Hu","author_inst":"Center for Discovery and Innovation, Hackensack Meridian Health"},{"author_name":"Haibo Yu","author_inst":"Center for Discovery and Innovation, Hackensack Meridian Health"},{"author_name":"Laura Zhao","author_inst":"Tianhe Stem Cell Biotechnologies Inc"},{"author_name":"Yeqian Zhao","author_inst":"Tianhe Stem Cell Biotechnologies Inc"},{"author_name":"Yong Zhao","author_inst":"Center for Discovery and Innovation, Hackensack Meridian Health"},{"author_name":"Silvia Renica","author_inst":"University of Milan"},{"author_name":"Federica Giardina","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Federica Novazzi","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Stefano Gaiarsa","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Elisa Matarazzo","author_inst":"University of Milan"},{"author_name":"Maria Antonello","author_inst":"University of Milan"},{"author_name":"Chiara Vismara","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Roberto Fumagalli","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Oscar Massimiliano Epis","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Massimo Puoti","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Carlo Federico Perno","author_inst":"University of Milan"},{"author_name":"Fausto Baldanti","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"immunology"},{"rel_doi":"10.1101\/2020.07.12.20151878","rel_title":"Inverted covariate effects for mutated 2nd vs 1st waveCovid-19: high temperature spread biased for young","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.12.20151878","rel_abs":"(1) Background: Here, we characterize COVID-19 2nd waves, following a study presenting negative associations between 1st wave COVID-19 spread parameters and temperature; (2) Methods: Visual examinations of daily increase in confirmed COVID-19 cases in 124 countries, determined 1st and 2nd waves in 28 countries; (3) Results: 1st wave spread rate increases with country mean elevation, temperature, time since wave onset, and median age. Spread rates decrease above 1000m, indicating high UV decrease spread rate. For 2nd waves, associations are opposite: viruses adapted to high temperature and to infect young populations. Earliest 2nd waves started April 5-7 at mutagenic high elevations (Armenia, Algeria). 2nd waves occurred also at warm-to-cold season transition (Argentina, Chile). Spread decreases in most (77%) countries. Death-to-total case ratios decrease during the 2nd wave, also when comparing with the same period for countries where the 1st wave is ongoing. In countries with late 1st wave onset, spread rates fit better 2nd than 1st wave-temperature patterns; In countries with ageing populations (examples: Japan, Sweden, Ukraine), 2nd waves only adapted to spread at higher temperatures, not to infect children. (4) Conclusions: 1st wave viruses evolved towards lower spread and mortality. 2nd wave mutant COVID-19 strain(s) adapted to higher temperature, infecting children and replace (also in cold conditions) 1st wave COVID-19 strains. Counterintuitively, low spread strains replace high spread strains, rendering prognostics and extrapolations uncertain.","rel_num_authors":5,"rel_authors":[{"author_name":"Herv\u00e9 Seligmann","author_inst":"University Grenoble Alpes and The Hebrew University of Jerusalem"},{"author_name":"Siham Iggui","author_inst":"University Grenoble Alpes"},{"author_name":"Mustapha Rachdi","author_inst":"University Grenoble Alpes"},{"author_name":"Nicolas Vuillerme","author_inst":"University Grenoble Alpes"},{"author_name":"Jacques Demongeot","author_inst":"University Grenoble Alpes"},{"author_name":"Yong Zhao","author_inst":"Center for Discovery and Innovation, Hackensack Meridian Health"},{"author_name":"Silvia Renica","author_inst":"University of Milan"},{"author_name":"Federica Giardina","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Federica Novazzi","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Stefano Gaiarsa","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Elisa Matarazzo","author_inst":"University of Milan"},{"author_name":"Maria Antonello","author_inst":"University of Milan"},{"author_name":"Chiara Vismara","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Roberto Fumagalli","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Oscar Massimiliano Epis","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Massimo Puoti","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Carlo Federico Perno","author_inst":"University of Milan"},{"author_name":"Fausto Baldanti","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_no","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.07.17.20156109","rel_title":"A New Adaptive Logistic Model for Epidemics and the Resurgence of COVID-19 in the United States","rel_date":"2020-07-20","rel_site":"medRxiv","rel_link":"https:\/\/medrxiv.org\/cgi\/content\/short\/2020.07.17.20156109","rel_abs":"The Adaptive Logistic Model (ALM) of epidemics incorporates the results of infection mitigation effects on the course of an epidemic, and well describes the histories of the COVID-19 epidemics in many countries, including the United States. In particular, it is much more successful than is a basic logistic model. However, in the U.S. these mitigation efforts have recently been relaxed in many places, resulting in the second peak in infections that started in late May of 2020. In this paper the ALM is modified to account for the relaxation of these mitigation effects, leading to the Adaptive Logistic Model 2 (ALM-2). The ALM-2 is then used to understand quantitatively the second peak of COVID-19 cases. The ALM-2 is also successfully applied to the data on deaths even though they do not yet show a second peak.","rel_num_authors":1,"rel_authors":[{"author_name":"David H Roberts","author_inst":"Brandeis University"},{"author_name":"Siham Iggui","author_inst":"University Grenoble Alpes"},{"author_name":"Mustapha Rachdi","author_inst":"University Grenoble Alpes"},{"author_name":"Nicolas Vuillerme","author_inst":"University Grenoble Alpes"},{"author_name":"Jacques Demongeot","author_inst":"University Grenoble Alpes"},{"author_name":"Yong Zhao","author_inst":"Center for Discovery and Innovation, Hackensack Meridian Health"},{"author_name":"Silvia Renica","author_inst":"University of Milan"},{"author_name":"Federica Giardina","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Federica Novazzi","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Stefano Gaiarsa","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Elisa Matarazzo","author_inst":"University of Milan"},{"author_name":"Maria Antonello","author_inst":"University of Milan"},{"author_name":"Chiara Vismara","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Roberto Fumagalli","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Oscar Massimiliano Epis","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Massimo Puoti","author_inst":"ASST Grande Ospedale Metropolitano Niguarda"},{"author_name":"Carlo Federico Perno","author_inst":"University of Milan"},{"author_name":"Fausto Baldanti","author_inst":"Fondazione IRCCS Policlinico San Matteo"},{"author_name":"Paola Reynoso-Lobo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"PUBLISHAHEADOFPRINT","category":"epidemiology"},{"rel_doi":"10.1101\/2020.07.18.209270","rel_title":"Cryo-electron Microscopy and Exploratory Antisense Targeting of the 28-kDa Frameshift Stimulation Element from the SARS-CoV-2 RNA Genome","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.18.209270","rel_abs":"Drug discovery campaigns against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are beginning to target the viral RNA genome1, 2. The frameshift stimulation element (FSE) of the SARS-CoV-2 genome is required for balanced expression of essential viral proteins and is highly conserved, making it a potential candidate for antiviral targeting by small molecules and oligonucleotides3-6. To aid global efforts focusing on SARS-CoV-2 frameshifting, we report exploratory results from frameshifting and cellular replication experiments with locked nucleic acid (LNA) antisense oligonucleotides (ASOs), which support the FSE as a therapeutic target but highlight difficulties in achieving strong inactivation. To understand current limitations, we applied cryogenic electron microscopy (cryo-EM) and the Ribosolve7 pipeline to determine a three-dimensional structure of the SARS-CoV-2 FSE, validated through an RNA nanostructure tagging method. This is the smallest macromolecule (88 nt; 28 kDa) resolved by single-particle cryo-EM at subnanometer resolution to date. The tertiary structure model, defined to an estimated accuracy of 5.9 [A], presents a topologically complex fold in which the 5' end threads through a ring formed inside a three-stem pseudoknot. Our results suggest an updated model for SARS-CoV-2 frameshifting as well as binding sites that may be targeted by next generation ASOs and small molecules.","rel_num_authors":19,"rel_authors":[{"author_name":"Kaiming Zhang","author_inst":"Stanford University"},{"author_name":"Ivan N. Zheludev","author_inst":"Stanford University"},{"author_name":"Rachel J. Hagey","author_inst":"Stanford University"},{"author_name":"Marie Teng-Pei Wu","author_inst":"Harvard University"},{"author_name":"Raphael Haslecker","author_inst":"Harvard University"},{"author_name":"Yixuan J. Hou","author_inst":"University of North Carolina at Chapel Hill"},{"author_name":"Rachael Kretsch","author_inst":"Stanford University"},{"author_name":"Grigore D. Pintilie","author_inst":"Stanford University"},{"author_name":"Ramya Rangan","author_inst":"Stanford University"},{"author_name":"Wipapat Kladwang","author_inst":"Stanford University"},{"author_name":"Shanshan Li","author_inst":"Stanford University"},{"author_name":"Edward A. Pham","author_inst":"Stanford University"},{"author_name":"Claire Bernardin","author_inst":"Stanford University"},{"author_name":"Ralph S. Baric","author_inst":"University of North Carolina at Chapel Hill"},{"author_name":"Timothy P. Sheahan","author_inst":"University of North Carolina at Chapel Hill"},{"author_name":"Victoria Dsouza","author_inst":"Harvard University"},{"author_name":"Jeffrey S. Glenn","author_inst":"Stanford University"},{"author_name":"Wah Chiu","author_inst":"Stanford University"},{"author_name":"Rhiju Das","author_inst":"Stanford University"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_no","type":"new results","category":"biochemistry"},{"rel_doi":"10.1101\/2020.07.18.210013","rel_title":"The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.18.210013","rel_abs":"The search for successful therapies of infections with the coronavirus SARS-CoV-2 is ongoing. We tested inhibition of host cell nucleotide synthesis as a promising strategy to decrease the replication of SARS-CoV-2-RNA, thus diminishing the formation of virus progeny. Methotrexate (MTX) is an established drug for cancer therapy and to induce immunosuppression. The drug inhibits dihydrofolate reductase and other enzymes required for the synthesis of nucleotides. Strikingly, the replication of SARS-CoV-2 was inhibited by MTX in therapeutic concentrations around 1 M, leading to more than 1000-fold reductions in virus progeny in Vero C1008 (Vero E6) as well as Calu-3 cells. Virus replication was more sensitive to equivalent concentrations of MTX than of the established antiviral agent remdesivir. MTX strongly diminished the synthesis of viral structural proteins and the amount of released virus RNA. Virus replication and protein synthesis were rescued by folinic acid (leucovorin) and also by inosine, indicating that purine depletion is the principal mechanism that allows MTX to reduce virus RNA synthesis. The combination of MTX with remdesivir led to synergistic impairment of virus replication, even at 300 nM MTX. The use of MTX in treating SARS-CoV-2 infections still awaits further evaluation regarding toxicity and efficacy in infected organisms, rather than cultured cells. Within the frame of these caveats, however, our results raise the perspective of a two-fold benefit from repurposing MTX for treating COVID-19. Firstly, its previously known ability to reduce aberrant inflammatory responses might dampen respiratory distress. In addition, its direct antiviral activity described here would limit the dissemination of the virus.\n\nSIGNIFICANCEO_LIMTX is one of the earliest cancer drugs to be developed, giving rise to seven decades of clinical experience. It is on the World Health Organizations List of Essential Medicines, can be administered orally or parenterally, and its costs are at single digit {euro} or $ amounts\/day for standard treatment. In case of its successful further preclinical evaluation for treating SARS-CoV-2 infections, its repurposing to treat COVID-19 would thus be feasible, especially under low-resource conditions.\nC_LIO_LIAdditional drugs exist to interfere with the synthesis of nucleotides, e.g. additional folate antagonists, inhibitors of GMP synthetase, or inhibitors of dihydroorotate dehydrogenase (DHODH). Such inhibitors have been approved as drugs for different purposes and might represent further therapeutic options against infections with SARS-CoV-2\nC_LIO_LIRemdesivir is currently the most established drug for treating COVID-19. Our results argue that MTX and remdesivir, even at moderate concentrations, can act in a synergistic fashion to repress virus replication to a considerably greater extent than either drug alone.\nC_LIO_LICOVID-19, in its severe forms, is characterized by pneumonia and acute respiratory distress syndrome, and additional organ involvements. These manifestations are not necessarily a direct consequence of virus replication and cytopathic effects, but rather a result of an uncontrolled inflammatory and immune response. Anti-inflammatory drugs such as glucocorticoids are thus being evaluated for treating COVID-19. However, this bears the risk of re-activating virus spread by suppressing a sufficient and specific immune response. In this situation, it is tempting to speculate that MTX might suppress both excessive inflammation as well as virus replication at the same time, thus limiting both the pathogenesis of pneumonia and also the spread of virus within a patient.\nC_LI","rel_num_authors":16,"rel_authors":[{"author_name":"Kim M Stegmann","author_inst":"University Medical Center Goettingen"},{"author_name":"Antje Dickmanns","author_inst":"University Medical Center Goettingen"},{"author_name":"Sabrina Gerber","author_inst":"University Medical Center Goettingen"},{"author_name":"Vella Nikolova","author_inst":"University Medical Center Goettingen"},{"author_name":"Luisa Klemke","author_inst":"University Medical Center Goettingen"},{"author_name":"Valentina Manzini","author_inst":"University Medical Center Goettingen"},{"author_name":"Denise Schloesser","author_inst":"University Medical Center Goettingen"},{"author_name":"Cathrin Bierwirth","author_inst":"University Medical Center Goettingen"},{"author_name":"Julia Freund","author_inst":"University Medical Center Goettingen"},{"author_name":"Maren Sitte","author_inst":"University Medical Center Goettingen"},{"author_name":"Raimond Lugert","author_inst":"University Medical Center Goettingen"},{"author_name":"Gabriela Salinas","author_inst":"University Medical Center Goettingen"},{"author_name":"Dirk Goerlich","author_inst":"Max Planck Institute of Biophysical Chemistry"},{"author_name":"Bernd Wollnik","author_inst":"University Medical Center Goettingen"},{"author_name":"Uwe Gross","author_inst":"University Medical Center Goettingen"},{"author_name":"Matthias Dobbelstein","author_inst":"University Medical Center Goettingen"},{"author_name":"Jeffrey S. Glenn","author_inst":"Stanford University"},{"author_name":"Wah Chiu","author_inst":"Stanford University"},{"author_name":"Rhiju Das","author_inst":"Stanford University"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by","type":"new results","category":"molecular biology"},{"rel_doi":"10.1101\/2020.07.19.179101","rel_title":"Haplotype Explorer: an infection cluster visualization tool for spatiotemporal dissection of the COVID-19 pandemic","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.19.179101","rel_abs":"The worldwide eruption of COVID-19 that began in Wuhan, China in late 2019 reached 10 million cases by late June 2020. In order to understand the epidemiological landscape of the COVID-19 pandemic, many studies have attempted to elucidate phylogenetic relationships between collected viral genome sequences using haplotype networks. However, currently available applications for network visualization are not suited to understand the COVID-19 epidemic spatiotemporally, due to functional limitations That motivated us to develop Haplotype Explorer, an intuitive tool for visualizing and exploring haplotype networks. Haplotype Explorer enables people to dissect epidemiological consequences via interactive node filters to provide spatiotemporal perspectives on multimodal spectra of infectious diseases, including introduction, outbreak, expansion, and containment, for given regions and time spans. Here, we demonstrate the effectiveness of Haplotype Explorer by showing an example of its visualization and features. The demo using SARS-CoV-2 genome sequences is available at https:\/\/github.com\/TKSjp\/HaplotypeExplorer\n\nSummaryA lot of software for network visualization are available, but existing software have not been optimized to infection cluster visualization against the current worldwide invasion of COVID-19 started since 2019. To reach the spatiotemporal understanding of its epidemics, we developed Haplotype Explorer. It is superior to other applications in the point of generating HTML distribution files with metadata searches which interactively reflects GISAID IDs, locations, and collection dates. Here, we introduce the features and products of Haplotype Explorer, demonstrating the time-dependent snapshots of haplotype networks inferred from total of 4,282 SARS-CoV-2 genomes.","rel_num_authors":7,"rel_authors":[{"author_name":"Tetsuro Kawano-Sugaya","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Koji Yatsu","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Tsuyoshi Sekizuka","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Kentaro Itokawa","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Masanori Hashino","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Rina Tanaka","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Makoto Kuroda","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Cathrin Bierwirth","author_inst":"University Medical Center Goettingen"},{"author_name":"Julia Freund","author_inst":"University Medical Center Goettingen"},{"author_name":"Maren Sitte","author_inst":"University Medical Center Goettingen"},{"author_name":"Raimond Lugert","author_inst":"University Medical Center Goettingen"},{"author_name":"Gabriela Salinas","author_inst":"University Medical Center Goettingen"},{"author_name":"Dirk Goerlich","author_inst":"Max Planck Institute of Biophysical Chemistry"},{"author_name":"Bernd Wollnik","author_inst":"University Medical Center Goettingen"},{"author_name":"Uwe Gross","author_inst":"University Medical Center Goettingen"},{"author_name":"Matthias Dobbelstein","author_inst":"University Medical Center Goettingen"},{"author_name":"Jeffrey S. Glenn","author_inst":"Stanford University"},{"author_name":"Wah Chiu","author_inst":"Stanford University"},{"author_name":"Rhiju Das","author_inst":"Stanford University"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"genomics"},{"rel_doi":"10.1101\/2020.07.18.210211","rel_title":"Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.18.210211","rel_abs":"Therapeutics targeting replication of SARS coronavirus 2 (SARS-CoV-2) are urgently needed. Coronaviruses rely on host membranes for entry, establishment of replication centers and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and are actively being pursued as treatments for other conditions. Here, we tested small molecule inhibitors that target membrane dynamics or lipid metabolism. Included were inhibitors of the PI3 kinase VPS34, which functions in autophagy, endocytosis and other processes; Orlistat, an inhibitor of lipases and fatty acid synthetase, is approved by the FDA as a treatment for obesity; and Triacsin C which inhibits long chain fatty acyl-CoA synthetases. VPS34 inhibitors, Orlistat and Triacsin C inhibited virus growth in Vero E6 cells and in the human airway epithelial cell line Calu-3, acting at a post-entry step in the virus replication cycle. Of these the VPS34 inhibitors exhibit the most potent activity.","rel_num_authors":5,"rel_authors":[{"author_name":"Jesus A. Silvas","author_inst":"Georgia State University"},{"author_name":"Alexander S Jureka","author_inst":"Georgia State University"},{"author_name":"Anthony M. Nicolini","author_inst":"Axion Biosystems, Inc."},{"author_name":"Stacie A. Chvatal","author_inst":"Axion Biosystems, Inc."},{"author_name":"Christopher F. Basler","author_inst":"Georgia State University"},{"author_name":"Rina Tanaka","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Makoto Kuroda","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Cathrin Bierwirth","author_inst":"University Medical Center Goettingen"},{"author_name":"Julia Freund","author_inst":"University Medical Center Goettingen"},{"author_name":"Maren Sitte","author_inst":"University Medical Center Goettingen"},{"author_name":"Raimond Lugert","author_inst":"University Medical Center Goettingen"},{"author_name":"Gabriela Salinas","author_inst":"University Medical Center Goettingen"},{"author_name":"Dirk Goerlich","author_inst":"Max Planck Institute of Biophysical Chemistry"},{"author_name":"Bernd Wollnik","author_inst":"University Medical Center Goettingen"},{"author_name":"Uwe Gross","author_inst":"University Medical Center Goettingen"},{"author_name":"Matthias Dobbelstein","author_inst":"University Medical Center Goettingen"},{"author_name":"Jeffrey S. Glenn","author_inst":"Stanford University"},{"author_name":"Wah Chiu","author_inst":"Stanford University"},{"author_name":"Rhiju Das","author_inst":"Stanford University"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_by_nc_nd","type":"new results","category":"microbiology"},{"rel_doi":"10.1101\/2020.07.19.210492","rel_title":"CETSA MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.19.210492","rel_abs":"The reuse of pre-existing small molecules for a novel emerging disease threat is a rapid measure to discover unknown applications for previously validated therapies. A pertinent and recent example where such strategy could be employed is in the fight against COVID-19. Therapies designed or discovered to target viral proteins also have off-target effects on the host proteome when employed in a complex physiological environment. This study aims to assess these host cell targets for a panel of FDA approved antiviral compounds including Remdesivir, using the cellular thermal shift assay (CETSA(R)) coupled to mass spectrometry (CETSA MS) in non-infected cells. CETSA MS is a powerful method to delineate direct and indirect interactions between small molecules and protein targets in intact cells. Biologically active compounds can induce changes in thermal stability, in their primary binding partners as well as in proteins that in turn interact with the direct targets. Such engagement of host targets by antiviral drugs may contribute to the clinical effect against the virus but can also constitute a liability. We present here a comparative study of CETSA molecular target engagement fingerprints of antiviral drugs to better understand the link between off-targets and efficacy.","rel_num_authors":4,"rel_authors":[{"author_name":"Tomas Friman","author_inst":"Pelago Bioscience"},{"author_name":"Alexey Chernobrovkin","author_inst":"Pelago Bioscience"},{"author_name":"Daniel Martinez Molina","author_inst":"Pelago Bioscience"},{"author_name":"Laurence H Arnold","author_inst":"Pelago Bioscience"},{"author_name":"Christopher F. Basler","author_inst":"Georgia State University"},{"author_name":"Rina Tanaka","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Makoto Kuroda","author_inst":"National Institute of Infectious Diseases"},{"author_name":"Cathrin Bierwirth","author_inst":"University Medical Center Goettingen"},{"author_name":"Julia Freund","author_inst":"University Medical Center Goettingen"},{"author_name":"Maren Sitte","author_inst":"University Medical Center Goettingen"},{"author_name":"Raimond Lugert","author_inst":"University Medical Center Goettingen"},{"author_name":"Gabriela Salinas","author_inst":"University Medical Center Goettingen"},{"author_name":"Dirk Goerlich","author_inst":"Max Planck Institute of Biophysical Chemistry"},{"author_name":"Bernd Wollnik","author_inst":"University Medical Center Goettingen"},{"author_name":"Uwe Gross","author_inst":"University Medical Center Goettingen"},{"author_name":"Matthias Dobbelstein","author_inst":"University Medical Center Goettingen"},{"author_name":"Jeffrey S. Glenn","author_inst":"Stanford University"},{"author_name":"Wah Chiu","author_inst":"Stanford University"},{"author_name":"Rhiju Das","author_inst":"Stanford University"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_no","type":"new results","category":"pharmacology and toxicology"},{"rel_doi":"10.1101\/2020.07.18.206946","rel_title":"De novo design of modular and tunable allosteric biosensors","rel_date":"2020-07-20","rel_site":"bioRxiv","rel_link":"https:\/\/biorxiv.org\/cgi\/content\/short\/2020.07.18.206946","rel_abs":"Naturally occurring allosteric protein switches have been repurposed for developing novel biosensors and reporters for cellular and clinical applications 1, but the number of such switches is limited, and engineering them is often challenging as each is different. Here, we show that a very general class of allosteric protein-based biosensors can be created by inverting the flow of information through de novo designed protein switches in which binding of a peptide key triggers biological outputs of interest 2. Using broadly applicable design principles, we allosterically couple binding of protein analytes of interest to the reconstitution of luciferase activity and a bioluminescent readout through the association of designed lock and key proteins. Because the sensor is based purely on thermodynamic coupling of analyte binding to switch activation, only one target binding domain is required, which simplifies sensor design and allows direct readout in solution. We demonstrate the modularity of this platform by creating biosensors that, with little optimization, sensitively detect the anti-apoptosis protein Bcl-2, the hIgG1 Fc domain, the Her2 receptor, and Botulinum neurotoxin B, as well as biosensors for cardiac Troponin I and an anti-Hepatitis B virus (HBV) antibody that achieve the sub-nanomolar sensitivity necessary to detect clinically relevant concentrations of these molecules. Given the current need for diagnostic tools for tracking COVID-19 3, we use the approach to design sensors of antibodies against SARS-CoV-2 protein epitopes and of the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. The latter, which incorporates a de novo designed RBD binder, has a limit of detection of 15pM with an up to seventeen fold increase in luminescence upon addition of RBD. The modularity and sensitivity of the platform should enable the rapid construction of sensors for a wide range of analytes and highlights the power of de novo protein design to create multi-state protein systems with new and useful functions.","rel_num_authors":15,"rel_authors":[{"author_name":"Alfredo Quijano-Rubio","author_inst":"University of Washington"},{"author_name":"Hsien-Wei Yeh","author_inst":"University of Washington"},{"author_name":"Jooyoung Park","author_inst":"University of Washington"},{"author_name":"Hansol Lee","author_inst":"KAIST Institute for the Biocentury"},{"author_name":"Robert A. Langan","author_inst":"University of Washington"},{"author_name":"Scott E. Boyken","author_inst":"University of Washington"},{"author_name":"Marc J. Lajoie","author_inst":"University of Washington"},{"author_name":"Longxing Cao","author_inst":"University of Washington"},{"author_name":"Cameron M. Chow","author_inst":"University of Washington"},{"author_name":"Marcos C. Miranda","author_inst":"University of Washington"},{"author_name":"Jimin Wi","author_inst":"Kangwon National University"},{"author_name":"Hyo Jeong Hong","author_inst":"Kangwon National University"},{"author_name":"Lance Stewart","author_inst":"University of Washington"},{"author_name":"Byung-Ha Oh","author_inst":"University of Washington, KAIST Institute for the Biocentury"},{"author_name":"David Baker","author_inst":"University of Washington"},{"author_name":"Matthias Dobbelstein","author_inst":"University Medical Center Goettingen"},{"author_name":"Jeffrey S. Glenn","author_inst":"Stanford University"},{"author_name":"Wah Chiu","author_inst":"Stanford University"},{"author_name":"Rhiju Das","author_inst":"Stanford University"},{"author_name":"Alma R. Marroquin-Escamilla","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jessica G. Herrera-Gamboa","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Fatima M. Alvarado-Monroy","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Claudia D. Aguayo-Millan","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Francisco F. Villegas-Macedo","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Jesus E. Flores-Osorio","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Daniel Davila-Gonzalez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Maria E. Diaz-Sanchez","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Guillermo Torre-Amione","author_inst":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico"},{"author_name":"Armin Schultz","author_inst":"CRS Clinical Research Services Mannheim GmbH"},{"author_name":"Pei-Yong Shi","author_inst":"University of Texas Medical Branch"},{"author_name":"Camila Fontes-Garfias","author_inst":"University of Texas Medical Branch"},{"author_name":"John L Perez","author_inst":"Pfizer"},{"author_name":"Kena A Swanson","author_inst":"Pfizer"},{"author_name":"Jakob Loschko","author_inst":"Pfizer"},{"author_name":"Ingrid L Scully","author_inst":"Pfizer"},{"author_name":"Mark Cutler","author_inst":"Pfizer"},{"author_name":"Warren Kalina","author_inst":"Pfizer"},{"author_name":"Christos A Kyratsous","author_inst":"Regeneron Pharmaceuticals, Inc."},{"author_name":"David Cooper","author_inst":"Pfizer"},{"author_name":"Philip R Dormitzer","author_inst":"Pfizer"},{"author_name":"Kathrin U Jansen","author_inst":"Pfizer"},{"author_name":"Oezlem Tuereci","author_inst":"BioNTech"}],"version":"1","license":"cc_no","type":"new results","category":"synthetic biology"}]}



